Document Detail

Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study.
MedLine Citation:
PMID:  7557824     Owner:  NLM     Status:  MEDLINE    
Fifty-three consecutive patients with active duodenal ulcer (DU) were randomly included in a double-blind, double-dummy study to test the healing and relapsing rate of two treatment regimens: famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing of the ulcer and colloidal bismuth (CBS) (240 mg bid) for 4-8 weeks, followed by placebo maintenance treatment. The results of the short term period confirmed the efficacy of CBS in healing DU (24/25 in CBS group and 19/23 in famotidine group). However, the relapse rate in the CBS-treated group was higher (77.8% at 12 months) than in the famotidine group (35.7%) (p = 0.041). Only 7 patients (41.2%) were cleared from Helicobacter pylori (HP) after CBS treatment. In conclusion, the high relapse rate observed in CBS treated patients may be related to the high percentage of patients with HP infection in the tested group and support the hypothesis that lack of efficacy of CBS in preventing DU recurrence is related to its poor eradication of HP.
E Masci; E Colombo; P A Testoni; L Fanti; M Guslandi; A Tittobello
Related Documents :
3740384 - The relationship of duration of fast to the volume and ph of gastric contents.
3661614 - Role of maintenance sucralfate in prevention of duodenal ulcer recurrence.
8422564 - Gastro-duodenal damage due to non-steroidal anti-inflammatory drugs in children.
6269234 - Ranitidine in uncomplicated duodenal ulceration. a double-blind endoscopically controll...
17889634 - Management of carpal tunnel syndrome in renal dialysis patients using an extended carpa...
6611584 - Prolonged red cell survival following in vitro treatment with potassium cyanate. a stud...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  9     ISSN:  0767-3981     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  1995  
Date Detail:
Created Date:  1995-11-21     Completed Date:  1995-11-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  280-3     Citation Subset:  IM    
Gastrointestinal Unit, Istituto Scientifico S. Raffaele, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antacids / administration & dosage,  therapeutic use*
Anti-Ulcer Agents / therapeutic use*
Bismuth / administration & dosage,  therapeutic use*
Colloids / administration & dosage,  therapeutic use
Double-Blind Method
Duodenal Ulcer / microbiology,  prevention & control*
Endoscopy, Gastrointestinal
Famotidine / therapeutic use*
Helicobacter pylori
Reg. No./Substance:
0/Antacids; 0/Anti-Ulcer Agents; 0/Colloids; 7440-69-9/Bismuth; 76824-35-6/Famotidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment.
Next Document:  New developments in the conduct and management of multi-center trials: an international review of cl...